Author

Xueli Li

Moffitt Cancer CenterORCID 0000-0002-3569-5899Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Approach:microscopy & imaging analysis· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Andriy MarusykiD· 1 shared Bin FangiD· 1 shared Bina DesaiiD· 1 shared Daria MiroshnychenkoiD· 1 shared Eric A. WelshiD· 1 shared Eric B. HauraiD· 1 shared Gabriela M. WrightiD· 1 shared Jodi L. KroegeriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andriy MarusykORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer via concurrent integrin and MET signaling

Qianqian Hu, Lily L. Remsing Rix, Bina Desai, Daria Miroshnychenko, Xueli Li, Eric A. Welsh, Bin Fang, Gabriela M. Wright, Neelkamal Chaudhary, Jodi L. Kroeger, Robert Charles Doebele, John M. Koomen, Eric B. Haura, Andriy Marusyk, Uwe Rix

This study identifies that CAFs confer ALK inhibitor resistance in EML4-ALK-driven lung cancer through both MET and integrin signaling pathways, and shows that targeting both pathways improves treatment efficacy.

Science Signaling · Dec 23, 2025Peer-reviewedCancer Biology